ImproveR International (BI-001-IM)

Nycomed

Status: Completed

Conditions: Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

Treatments: Drug: Bivalirudin

Study type: Observational

Funder types: Industry

Identifiers

NCT00290849

BI-001-IM

Details and patient eligibility

About

The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following objectives;

• examine the aspects of safety and effectiveness of bivalirudin
• gain experience regarding the characteristics of patients in bivalirudin treatment
• evaluate the handling of bivalirudin and its practicality

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

> 18 years, undergoing planned or urgent PCI with the intention to use bivalirudin as anticoagulant, written informed concent to entry of data information registry.

Exclusion criteria

None